Tailwinds' Take: not a moment of shining glory for the court system. This whole case is an ongoing fiasco that is just wasting dual resources of time and money. For a good take on it, go to www.rightofassembly.org. Eventually...
Tailwinds' Take: continued strategic interest in CDXC bodes well for future market acceptance of Tru Niagen. Revenues beat last Q and are in a very high growth mode. More clinical validation coming will continue to support the high valuation...
This was a very hectic week in the market, with major swings in the indexes and in our universe of smaller companies. Earnings season for most smaller companies is the first two weeks of August, which creates ample reasons...
Tailwinds' Take: great incremental growth. LOS ANGELES, Aug. 07, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) today reported second quarter 2019 financial results. “We successfully continue to build our global TRU NIAGEN brand and consequentially had another quarter strengthening our business...
In what is shaping up as a never-ending quest to provide newsletter coverage from anyplace not named "home", this week's letter comes from Raleigh, NC. I'm here to keep my daughter company for the weekend as she is toiling...
First Quarter 2019 Highlights vs. First Quarter 2018 Strong start to the year with $10.0 million of net sales, higher gross margins and increased marketing efficiency Continued progress building TRU NIAGEN into a global brand with top-line momentum TRU NIAGEN net...
LOS ANGELES, May 09, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that it has entered into a note purchase agreement for the sale of $10.0 million of convertible notes in a private placement.  The transaction was led by international strategic investors. The transaction...
LOS ANGELES, April 15, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today the latest milestone in its global expansion strategy for TRU NIAGEN®, with a strategic deal with specialty retailer Showcase in Toronto, Canada. Tru Niagen is now available in 36 Showcase stores...
LOS ANGELES, April 09, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) today reported that results of a new preclinical study showed that supplementation with the unique B3 vitamin nicotinamide riboside (NR, or Niagen®) helps maintain heart function in mice by stimulating a conserved...
Fourth Quarter 2018 Highlights vs. Fourth Quarter 2017 Entered into a global license and supply agreement with Nestlé Health Science (“NHSc”), which provides NHSc with the exclusive right to include TRU NIAGEN® in its branded medical nutrition products and...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.